Retrovirus studies showed that a transmissible agent can cause a tumour and, more unexpectedly, that a viral transforming gene can derive from an ordinary cellular gene. This connected infectious cancer models to the molecular control of normal cell growth.
Peyton Rous transmitted a chicken sarcoma using material from a tumour and showed that a cell-free filtrate could transmit the disease. The agent could therefore be separated from intact tumour cells, arguing against simple transplantation of the malignant cells as the explanation.[ref]
A sarcoma of the fowl transmissible by an agent separable from the tumor cells by Peyton Rous. pp. 397–411, transmission with material separated from tumour cells
This established a filterable tumour-causing agent, not yet its RNA genome, replication mechanism or a claim that every cancer is infectious. In repeating such an experiment, an uninoculated or sham-treated group and a preparation verified to lack viable donor cells would be essential comparators; host susceptibility and the preparation's retained infectivity would also matter.The later Rous sarcoma virus system made transformation experimentally tractable. Infected cultured fibroblasts can lose contact inhibition, change morphology and form foci against a background of untransformed cells. Such assays distinguish efficient transformation from the slower and more complex endpoint of tumour formation in an animal. Temperature-sensitive transforming mutants allow the phenotype to be switched by changing conditions, while transformation-defective viruses can still replicate. This separates a transforming function from the basic machinery required to produce virus.
The retroviral life cycle explains persistent genetic change. Viral RNA is copied into DNA by reverse transcriptase; the resulting DNA can integrate into the cellular genome as a provirus. Demonstration of RNA-dependent DNA synthesis in Rous-virus particles gave biochemical support to this route of information transfer.[ref]
RNA-dependent DNA polymerase in virions of Rous sarcoma virus by Howard M. Temin and others. pp. 1211–1213, RNA-dependent DNA synthesis in virion preparations
Template dependence, nuclease sensitivity and controls for contaminating cellular enzymes are needed to infer an RNA-templated polymerase rather than merely observe incorporation of labelled nucleotides. Integration then allows stable expression of viral genes through ordinary cellular transcription.Comparison of transforming and transformation-defective viral genomes identified v-src as a transforming determinant. A crucial next question was whether src-like sequence existed only in tumour viruses. A probe enriched for transformation-specific viral sequences hybridized to DNA from normal birds, including multiple avian species. This showed that related information was present in normal cellular genomes, with evolutionary conservation rather than only virus-associated occurrence.[ref]
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA by Dominique Stehelin and others. pp. 170–173, hybridization of transformation-related probe to normal avian DNA
The cellular counterpart, c-src, is a proto-oncogene: a normally regulated cellular gene that can become oncogenic when its expression or activity is altered. Viral capture and modification of cellular growth-control information therefore explain why a virus can carry a potent growth-deregulating gene.The Src product linked genotype to a biochemical mechanism. Its kinase activity was shown to phosphorylate tyrosine residues, establishing an unusual regulatory chemistry at the time and connecting transformation to deregulated protein phosphorylation.[ref]
Transforming gene product of Rous sarcoma virus phosphorylates tyrosine by Tony Hunter and others. pp. 1311–1315, identification of phosphotyrosine in kinase products
The viral product has altered regulation compared with normal cellular Src, so persistent signalling can disrupt growth, adhesion and cytoskeletal control. The lesson is not that a normally expressed proto-oncogene is inherently malignant: context, dosage and regulatory state matter. Immunoprecipitate kinase assays need controls because an associated kinase could otherwise be mistaken for the precipitated protein's catalytic activity; biochemical and genetic tests strengthen the attribution.Other retroviruses supplied a second route. Slowly transforming avian leukosis viruses need not carry a captured oncogene; integration near a cellular gene can alter its expression through viral regulatory sequences. Promoter-insertion studies of the MYC proto-oncogene demonstrated this principle.[ref]
Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis by W. S. Hayward and others. pp. 475–480, promoter insertion and cellular oncogene activation
Recurrent integrations near the same gene across independent tumours provide more persuasive evidence than one integration in one tumour, and expression and functional tests help distinguish a driver event from an incidental integration.Together these experiments established separable mechanisms of viral oncogene acquisition and insertional oncogenesis, revealed cellular proto-oncogenes and identified deregulated signalling as a cause of transformation. They do not imply that retroviral integration explains every tumour, or that a transformed culture has all the properties of an invasive cancer. Their wider importance is that normal growth-regulatory genes, when altered, can drive malignant behaviour even outside the original infectious setting.